NovoCure Ltd — Director's Dealing 2021

Apr 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-04-13

Reporting Person: Benaim Ely (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-13	Ordinary Shares	M	1833	$47.56	Acquired	35092	Direct
2021-04-13	Ordinary Shares	S	1833	$200	Disposed	33259	Direct
2021-04-13	Ordinary Shares	M	651	$83.30	Acquired	33910	Direct
2021-04-13	Ordinary Shares	S	651	$200	Disposed	33259	Direct
2021-04-13	Ordinary Shares	M	3474	$69.37	Acquired	36733	Direct
2021-04-13	Ordinary Shares	S	3474	$200	Disposed	33259	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-13	Options to Buy Ordinary Shares	$47.56	M	1833	Disposed	2029-05-07	Ordinary Shares (1833.0)	Direct
2021-04-13	Options to Buy Ordinary Shares	$83.3	M	651	Disposed	2029-07-30	Ordinary Shares (651.0)	Direct
2021-04-13	Options to Buy Ordinary Shares	$69.37	M	3474	Disposed	2030-03-02	Ordinary Shares (3474.0)	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.

F2: Fully vested as of the date hereof.